<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of
the</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of Earliest event
Reported): March 1, 2012</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTEA BIOSCIENCES GROUP, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified
in its charter)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; line-height: 115%; font-size: 10pt; text-align: center"><U>Delaware</U></TD>
    <TD STYLE="width: 36%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><U>000-51474</U></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="width: 32%; line-height: 115%; font-size: 10pt; text-align: center"><U>20-2903252</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; font-size: 10pt; text-align: center">(State or other jurisdiction of incorporation or organization)</TD>
    <TD STYLE="line-height: 115%; font-size: 10pt; text-align: center">(Commission File Number)</TD>
    <TD STYLE="line-height: 115%; font-size: 10pt; text-align: center">(IRS Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">955 Hartman Run Road</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Morgantown, West Virginia 26507</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(304) 292-2226</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&rsquo;s telephone number,
including area code)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;(Former name or former address,
if changed since last report)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><BR>
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (<U>see</U> General Instruction A.2. below):</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; line-height: 115%"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD STYLE="width: 3%; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 90%; line-height: 115%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Pre-commencement communications pursuant to Rule 13e-4(c)
        under the Exchange Act (17 CFR 240.13e-4(c))</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Item 1.01&#9;Entry into Material Definitive Agreement</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with
the terms of a private placement offering (the &ldquo;Offering&rdquo;) of<B> </B>up to 100 units (the &ldquo;Units&rdquo;), each
Unit consisting of 50,000 shares of common stock, par value $0.0001 per share (the &ldquo;Common Stock&rdquo;) and warrants to
purchase 25,000 shares of Common Stock (the &ldquo;Warrants&rdquo;), <FONT STYLE="color: black">during the period beginning on
the date of the declaration of the effectiveness of a registration statement relating to a firm commitment underwritten offering
covering the offer and sale of Common Stock for the account of the Company through the six month anniversary thereof, </FONT>each
of the officers and directors of Protea Biosciences Group, Inc. (the &ldquo;Company&rdquo;) <FONT STYLE="color: black">agreed not
to, subject to certain exemptions, directly or indirectly, offer, sell, hedge, or pledge any option or contract to purchase, sell,
grant any option, right or warrant to purchase or sell, or otherwise transfer or dispose of (or enter into any transaction or device
that is designed to, or could be expected to, result in the disposition by any person at any time in the future), any securities
of the Company beneficially owned by such person, pursuant to the terms and conditions of a lock-up agreement (the &ldquo;Lock-up
Agreement&rdquo;) by and between the Company and each such officer and director. </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The above description
of the Lock-up Agreement is intended to be a summary only and is qualified in its entirety by the terms and conditions of the Lock-up
Agreement, attached to this Current Report on Form 8-K as Exhibit 10.1.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Item 3.02&#9;Recent Sales of Unregistered Securities.
</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 1,
2012 (the &ldquo;Final Closing Date&rdquo;), in connection with the Offering of Units described above, the Company issued an aggregate
of 1,370,000 shares of Common Stock and Warrants to purchase an aggregate of 685,000 shares of Common Stock at a per Unit purchase
price equal to $100,000, for aggregate gross proceeds equal to $2,740,000. The Warrants are exercisable at an exercise price of
$2.25 per share any time after the date of issuance (the &ldquo;Issue Date&rdquo;) until the earlier of (i) a Qualified Public
Offering (as defined below), or (ii) 5:00 p.m. Eastern time on the fifth anniversary of the Issue Date of the Warrant. The term
&ldquo;Qualified Public Offering&rdquo; means the closing of a firm commitment underwritten offering pursuant to an effective
registration statement under the Securities Act covering the offer and sale of Common Stock for the account of the Company in
which the net cash proceeds to the Company (after deduction of underwriting discounts, commissions and fees) are at least $15,000,000.
The placement agent (the "Placement Agent") in the Offering received total cash commissions equal to $140,000, which amount represents
8% of the total gross proceeds received from investors that participated in the Offering and were introduced to the Company by
the Placement Agent. In addition, the Placement Agent also received warrants to purchase an aggregate of 70,000 shares of Common
Stock at an exercise price of $2.20 per share (the "Placement Agent Warrants"). The Placement Agent Warrants are exercisable any
time after the Issue Date until the earlier of (1) a Qualified Public Offering or (ii) 5:00 p.m. Eastern time on the fifth anniversary
of the Issue Date.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Units
were issued to accredited investors in accordance with <FONT STYLE="color: black">Rule&nbsp;506 of Regulation D under the Securities
Act of 1933, as amended. </FONT>The Company did not engage in any general advertisement or general solicitation in connection with
the offering of the Units.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The above description
of the Warrant is intended to be a summary only and is qualified in its entirety by the terms of the Warrant attached hereto as
Exhibit 4.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Item 7.01. &#9;Regulation FD</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">Filed as Exhibit
99.1 to this Current Report on Form 8-K is an Executive Summary of the Company filed in accordance with Regulation FD.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Item 9.01.&#9;Exhibits and Financial Statements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.1.&#9;Form of Warrant issued to Investors
in the Offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">10.1&#9;Form of Lock-up Agreement by
and between the Company and each officer and director.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">99.1&#9;Executive Summary.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 5pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 5pt 0; text-align: justify; text-indent: 0.5in">Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 5pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 5pt 0">Dated: March 6, 2012</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 5pt 0 5pt 3.5in"><B>PROTEA BIOSCIENCES GROUP, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 5pt 0 5pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 3.5in">By: <U>/s/ Stephen Turner</U></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 3.5in">Stephen Turner</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 3.5in">Chief Executive Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 3.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 5pt 0 5pt 3.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v304787_8-k.htm", "description": "CURRENT REPORT", "secsgml_size_bytes": 16422}]
{"company-data": {"conformed-name": "Protea Biosciences Group, Inc.", "cik": "0001335103", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-51474", "film-number": "12669924"}, "business-address": {"street1": "955 HARTMAN RUN ROAD", "city": "MORGANTOWN", "state": "WV", "zip": "26507", "phone": "304 292-2226"}, "mail-address": {"street1": "955 HARTMAN RUN ROAD", "city": "MORGANTOWN", "state": "WV", "zip": "26507"}, "former-company": [{"former-conformed-name": "Protea Biosciences Inc.", "date-changed": "20110908"}, {"former-conformed-name": "SRKP 5 INC", "date-changed": "20050803"}]}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of Earliest event
Reported): March 1, 2012
PROTEA BIOSCIENCES GROUP, INC.
(Exact name of registrant as specified
in its charter)
Delaware
000-51474
20-2903252
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(IRS Employer Identification No.)
955 Hartman Run Road
Morgantown, West Virginia 26507
(Address of principal executive offices)
(304) 292-2226
(Registrant's telephone number,
including area code)
(Former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
£
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c)
        under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01	Entry into Material Definitive Agreement
In connection with
the terms of a private placement offering (the "Offering") of
up to 100 units (the "Units"), each
Unit consisting of 50,000 shares of common stock, par value $0.0001 per share (the "Common Stock") and warrants to
purchase 25,000 shares of Common Stock (the "Warrants"),
during the period beginning on
the date of the declaration of the effectiveness of a registration statement relating to a firm commitment underwritten offering
covering the offer and sale of Common Stock for the account of the Company through the six month anniversary thereof,
each
of the officers and directors of Protea Biosciences Group, Inc. (the "Company")
agreed not
to, subject to certain exemptions, directly or indirectly, offer, sell, hedge, or pledge any option or contract to purchase, sell,
grant any option, right or warrant to purchase or sell, or otherwise transfer or dispose of (or enter into any transaction or device
that is designed to, or could be expected to, result in the disposition by any person at any time in the future), any securities
of the Company beneficially owned by such person, pursuant to the terms and conditions of a lock-up agreement (the "Lock-up
Agreement") by and between the Company and each such officer and director.
The above description
of the Lock-up Agreement is intended to be a summary only and is qualified in its entirety by the terms and conditions of the Lock-up
Agreement, attached to this Current Report on Form 8-K as Exhibit 10.1.
Item 3.02	Recent Sales of Unregistered Securities.
As of March 1,
2012 (the "Final Closing Date"), in connection with the Offering of Units described above, the Company issued an aggregate
of 1,370,000 shares of Common Stock and Warrants to purchase an aggregate of 685,000 shares of Common Stock at a per Unit purchase
price equal to $100,000, for aggregate gross proceeds equal to $2,740,000. The Warrants are exercisable at an exercise price of
$2.25 per share any time after the date of issuance (the "Issue Date") until the earlier of (i) a Qualified Public
Offering (as defined below), or (ii) 5:00 p.m. Eastern time on the fifth anniversary of the Issue Date of the Warrant. The term
"Qualified Public Offering" means the closing of a firm commitment underwritten offering pursuant to an effective
registration statement under the Securities Act covering the offer and sale of Common Stock for the account of the Company in
which the net cash proceeds to the Company (after deduction of underwriting discounts, commissions and fees) are at least $15,000,000.
The placement agent (the "Placement Agent") in the Offering received total cash commissions equal to $140,000, which amount represents
8% of the total gross proceeds received from investors that participated in the Offering and were introduced to the Company by
the Placement Agent. In addition, the Placement Agent also received warrants to purchase an aggregate of 70,000 shares of Common
Stock at an exercise price of $2.20 per share (the "Placement Agent Warrants"). The Placement Agent Warrants are exercisable any
time after the Issue Date until the earlier of (1) a Qualified Public Offering or (ii) 5:00 p.m. Eastern time on the fifth anniversary
of the Issue Date.
The Units
were issued to accredited investors in accordance with
Rule 506 of Regulation D under the Securities
Act of 1933, as amended.
The Company did not engage in any general advertisement or general solicitation in connection with
the offering of the Units.
The above description
of the Warrant is intended to be a summary only and is qualified in its entirety by the terms of the Warrant attached hereto as
Exhibit 4.1 to this Current Report on Form 8-K.
Item 7.01. 	Regulation FD
Filed as Exhibit
99.1 to this Current Report on Form 8-K is an Executive Summary of the Company filed in accordance with Regulation FD.
Item 9.01.	Exhibits and Financial Statements
4.1.	Form of Warrant issued to Investors
in the Offering.
10.1	Form of Lock-up Agreement by
and between the Company and each officer and director.
99.1	Executive Summary.
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated: March 6, 2012
PROTEA BIOSCIENCES GROUP, INC.
By:
/s/ Stephen Turner
Stephen Turner
Chief Executive Officer